Bora CDMO Bora CDMO

X

Find Radio Compass News for Silmitasertib

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-ii--study-of-silmitasertib-in-patients-with-community-acquired-pneumonia-associated-with-viral-infection-in-taiwan-302094217.html

PR NEWSWIRE
20 Mar 2024

https://www.prnewswire.com/news-releases/senhwa-biosciences-received-us-fda-ind-approval-for-phase-ii-study-of-silmitasertib-in-patients-with-community-acquired-pneumonia-cap-associated-with-viral-infection-301994554.html

PR NEWSWIRE
21 Nov 2023

https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-first-patient-successfully-dosed-in-taiwan-phase-ii-study-of-silmitasertib-in-hospitalized-adults-with-covid-19-301982962.html

PR NEWSWIRE
09 Nov 2023

https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-ind-submission-to-us-fda-for-phase-ii-study-of-silmitasertib-in-patients-with-community-acquired-pneumonia-cap-associated-with-viral-infection-301961780.html

PR NEWSWIRE
19 Oct 2023

http://pharmabiz.com/NewsDetails.aspx?aid=157818&sid=2

PHARMABIZ
02 May 2023

https://www.prnewswire.com/news-releases/at-the-2022-aad-annual-meeting-senhwa-presents-positive-initial-data-from-clinical-trial-of-silmitasertib-used-to-treat-patients-with-advanced-basal-cell-carcinoma-301511415.html

PRNEWSWIRE
28 Mar 2022

https://www.prnewswire.com/news-releases/senhwas-silmitasertib-receives-us-fda-orphan-drug-designation-for-the-treatment-of-biliary-tract-cancer-301464631.html

PRNEWSWIRE
20 Jan 2022

https://www.prnewswire.com/news-releases/senhwas-silmitasertib-receives-us-fda-orphan-drug-designation-for-the-treatment-of-medulloblastoma-301447119.html

PRNEWSWIRE
17 Dec 2021

https://www.prnewswire.com/news-releases/senhwa-clinical-data-abstract-for-silmitasertib-in-patients-with-advanced-basal-cell-carcinoma-accepted-for-2022-aad-annual-meeting-301446148.html

PRNEWSWIRE
16 Dec 2021

https://www.clinicaltrialsarena.com/news/senhwa-positive-data-covid-trial/

CLINICALTRIALSARENA
21 Oct 2021

https://www.prnewswire.com/news-releases/senhwa-announces-acceptance-of-early-positive-covid-19-phase-ii-study-abstract-for-presentation-at-the-isirv-who-conference-301385476.html

PRNEWSWIRE
27 Sep 2021

https://www.prnewswire.com/news-releases/senhwas-silmitasertib-covid-19-drug-candidate-receives-positive-interim-review-from-data-monitoring-committee-to-proceed-301365769.html

PRNEWSWIRE
31 Aug 2021

https://www.prnewswire.com/news-releases/senhwas-silmitasertib-receives-us-fda-fast-track-designation-for-the-treatment-of-recurrent-sonic-hedgehog-driven-medulloblastoma-301358557.html

PRNEWSWIRE
18 Aug 2021

http://www.pharmabiz.com/NewsDetails.aspx?aid=135057&sid=2

PHARMABIZ
23 Jan 2021

https://www.prnewswire.com/news-releases/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-patients-with-severe-covid-19-301213001.html

PRNEWSWIRE
21 Jan 2021

https://www.biospace.com/article/releases/care-ga-receives-study-may-proceed-letter-from-us-fda-to-initiate-phase-ii-clinical-trial-of-senhwa-s-silmitasertib-in-covid-19-patients/

BIOSPACE
06 Nov 2020

https://www.prnewswire.com/news-releases/senhwa-announces-multiple-ind-application-submissions-to-us-fda-for-silmitasertib-as-a-potential-treatment-for-covid-19-301164719.html

PRNEWSWIRE
02 Nov 2020

https://en.prnasia.com/releases/global/senhwa-announces-multiple-ind-application-submissions-to-u-s-fda-for-silmitasertib-as-a-potential-treatment-for-covid-19-297038.shtml

PRNASIA
02 Nov 2020

https://www.biospectrumasia.com/news/39/16714/taiwan-reports-first-covid-19-patient-recovery-with-eind-silmitasertib-treatment.html

BIOSPECTRUM ASIA
15 Sep 2020

https://en.prnasia.com/releases/global/coronavirus-breakthrough-senhwa-reports-first-eind-silmitasertib-treated-severe-covid-19-patient-discharged-following-five-days-of-treatment-291291.shtml

PRNASIA
13 Sep 2020

https://en.prnasia.com/releases/global/senhwa-biosciences-s-silmitasertib-receives-rare-pediatric-disease-designation-from-u-s-fda-for-treatment-of-recurrent-sonic-hedgehog-medulloblastoma-284762.shtml

PRNASIA
07 Jul 2020

https://www.biospectrumasia.com/news/26/16230/senhwa-bio-explores-silmitasertib-for-covid-19-treatment.html

BIOSPECTRUMASIA
06 Jul 2020

https://www.prnewswire.com/news-releases/coronavirus-breakthrough-new-study-highlights-senhwa-biosciences-silmitasertib-as-potential-treatment-for-covid-19-301086613.html

PRNEWSWIRE
01 Jul 2020
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY